Antibe Therapeutics (TSE:ATE) Trading 13.5% Higher

Shares of Antibe Therapeutics Inc. (TSE:ATEGet Free Report) were up 13.5% during mid-day trading on Wednesday . The company traded as high as C$0.21 and last traded at C$0.21. Approximately 46,781 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 127,946 shares. The stock had previously closed at C$0.19.

Analyst Ratings Changes

Separately, Brookline Capital Management lowered Antibe Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 4th.

Check Out Our Latest Stock Report on ATE

Antibe Therapeutics Stock Performance

The company has a market capitalization of C$12.11 million, a price-to-earnings ratio of -0.53 and a beta of 0.31. The company has a current ratio of 10.06, a quick ratio of 9.58 and a debt-to-equity ratio of 0.29. The stock has a 50-day simple moving average of C$0.72 and a 200-day simple moving average of C$0.74.

Antibe Therapeutics (TSE:ATEGet Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported C($0.08) EPS for the quarter, beating analysts’ consensus estimates of C($0.12) by C$0.04. On average, analysts anticipate that Antibe Therapeutics Inc. will post 0.5314286 earnings per share for the current year.

About Antibe Therapeutics

(Get Free Report)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).

Further Reading

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.